Developing Therapies for Heart Failure With Preserved Ejection Fraction Current State and Future Directions

被引：248

作者：

Butler, Javed ^{[1
]}

Fonarow, Gregg C. ^{[2
]}

Zile, Michael R. ^{[3
,4
]}

Lam, Carolyn S. ^{[5
]}

Roessig, Lothar ^{[6
]}

Schelbert, Erik B. ^{[7
]}

Shah, Sanjiv J. ^{[8
]}

Ahmed, Ali ^{[9
]}

Bonow, Robert O. ^{[8
]}

Cleland, John G. F. ^{[10
]}

Cody, Robert J. ^{[11
]}

Chioncel, Ovidiu ^{[12
]}

Collins, Sean P. ^{[13
]}

Dunnmon, Preston ^{[14
]}

Filippatos, Gerasimos ^{[15
]}

Lefkowitz, Martin P. ^{[16
]}

Marti, Catherine N. ^{[1
]}

McMurray, John J. ^{[17
]}

Misselwitz, Frank ^{[6
]}

Nodari, Savina ^{[18
]}

O'Connor, Christopher ^{[19
]}

Pfeffer, Marc A. ^{[20
]}

Pieske, Burkert ^{[21
]}

Pitt, Bertram ^{[22
]}

Rosano, Giuseppe ^{[23
]}

Sabbah, Hani N. ^{[24
]}

Senni, Michele ^{[25
]}

Solomon, Scott D. ^{[20
]}

Stockbridge, Norman ^{[14
]}

Teerlink, John R. ^{[26
,27
]}

Georgiopoulou, Vasiliki V. ^{[1
]}

Gheorghiade, Mihai ^{[8
]}

机构：

[1] Emory Univ, Dept Med, Emory Cardiovasc Clin Res Inst, Atlanta, GA 30322 USA

[2] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA

[3] Med Univ S Carolina, Div Cardiol, Charleston, SC 29425 USA

[4] RHJ Dept Vet Affairs Med Ctr, Charleston, SC USA

[5] Natl Univ Hlth Syst, Cardiovasc Res Inst, Singapore, Singapore

[6] Bayer HealthCare, Global Clin Dev, Wuppertal, Germany

[7] Univ Pittsburgh, Dept Med, Med Ctr, Inst Heart & Vasc, Pittsburgh, PA USA

[8] Northwestern Univ, Dept Med, Ctr Cardiovasc Innovat, Feinberg Sch Med, Chicago, IL 60611 USA

[9] Univ Alabama Birmingham, Div Gerontol, Birmingham, AL USA

[10] Castle Hill Hosp, Hull York Med Sch, Dept Cardiol, Kingston Upon Hull, Yorks, England

[11] Janssen Pharmaceut, Cardiovasc & Metab Div, Raritan, NJ USA

[12] Inst Emergency Cardiovasc Dis, Cardiol, Bucharest, Romania

[13] Vanderbilt Univ, Dept Emergency Med, Nashville, TN 37235 USA

[14] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA

[15] Athens Univ Hosp, Dept Cardiol, Athens, Greece

[16] Novartis Pharmaceut Inc, E Hanover, NJ USA

[17] Univ Glasgow, Glasgow Cardiovasc Res Ctr, British Heart Fdn, Glasgow, Lanark, Scotland

[18] Univ Brescia, Div Cardiol, Brescia, Italy

[19] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA

[20] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA

[21] Med Univ Graz, Dept Cardiol, Graz, Austria

[22] Univ Michigan, Sch Med, Dept Med, Div Cardiol, Ann Arbor, MI 48104 USA

[23] Ctr Clin & Basic Sci, Rome, Italy

[24] Henry Ford Hosp, Dept Med, Detroit, MI 48202 USA

[25] Osped Papa Giovanni XXIII, Cardiovasc Dept, Bergamo, Italy

[26] Univ Calif San Francisco, San Francisco, CA 94143 USA

[27] San Francisco VA Med Ctr, San Francisco, CA USA

来源：

JACC-HEART FAILURE | 2014年 / 2卷 / 02期

关键词：

epidemiology; heart failure; preserved ejection fraction; prognosis; treatment; RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; VENTRICULAR DIASTOLIC DYSFUNCTION; CONVERTING ENZYME-INHIBITORS; PRIOR MYOCARDIAL-INFARCTION; NATRIURETIC PEPTIDE LEVELS; SINGLE-BLIND TRIAL; EXERCISE CAPACITY; SYSTOLIC FUNCTION; ELDERLY-PATIENTS;

D O I：

10.1016/j.jchf.2013.10.006

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The burden of heart failure with preserved ejection fraction (HFpEF) is considerable and is projected to worsen. To date, there are no approved therapies available for reducing mortality or hospitalizations for these patients. The pathophysiology of HFpEF is complex and includes alterations in cardiac structure and function, systemic and pulmonary vascular abnormalities, end-organ involvement, and comorbidities. There remain major gaps in our understanding of HFpEF pathophysiology. To facilitate a discussion of how to proceed effectively in future with development of therapies for HFpEF, a meeting was facilitated by the Food and Drug Administration and included representatives from academia, industry, and regulatory agencies. This document summarizes the proceedings from this meeting. (C) 2014 by the American College of Cardiology Foundation

引用

页码：97 / 112

页数：16

共 93 条

[1] EFFECTS OF ALTERATIONS IN PULMONARY VASCULAR RESISTANCE ON RIGHT VENTRICULAR FUNCTION [J].

ABEL, FL ;

WALDHAUSEN, JA .

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1967, 54 (06) :886-+

[2] Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial [J].

Abraham, William T. ;

Adamson, Philip B. ;

Bourge, Robert C. ;

Aaron, Mark F. ;

Costanzo, Maria Rosa ;

Stevenson, Lynne W. ;

Strickland, Warren ;

Neelagaru, Suresh ;

Raval, Nirav ;

Krueger, Steven ;

Weiner, Stanislav ;

Shavelle, David ;

Jeffries, Bradley ;

Yadav, Jay S. .

LANCET, 2011, 377 (9766) :658-666

[3] Effects of digoxin on morbidity and mortality in diastolic heart failure: The ancillary Digitalis Investigation Group trial [J].

Ahmed, Ali ;

Rich, Michael W. ;

Fleg, Jerome L. ;

Zile, Michael R. ;

Young, James B. ;

Kitzman, Dalane W. ;

Love, Thomas E. ;

Aronow, Wilbert S. ;

Adams, Kirkwood F., Jr. ;

Gheorghiade, Mihai .

CIRCULATION, 2006, 114 (05) :397-403

[4] Incremental Prognostic Significance of Peripheral Endothelial Dysfunction in Patients With Heart Failure With Normal Left Ventricular Ejection Fraction [J].

Akiyama, Eiichi ;

Sugiyama, Seigo ;

Matsuzawa, Yasushi ;

Konishi, Masaaki ;

Suzuki, Hiroyuki ;

Nozaki, Toshimitsu ;

Ohba, Keisuke ;

Matsubara, Junichi ;

Maeda, Hirofumi ;

Horibata, Yoko ;

Sakamoto, Kenji ;

Sugamura, Koichi ;

Yamamuro, Megumi ;

Sumida, Hitoshi ;

Kaikita, Koichi ;

Iwashita, Satomi ;

Matsui, Kunihiko ;

Kimura, Kazuo ;

Umemura, Satoshi ;

Ogawa, Hisao .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (18) :1778-1786

[5] Identifying Patients Hospitalized With Heart Failure at Risk for Unfavorable Future Quality of Life [J].

Allen, Larry A. ;

Gheorghiade, Mihai ;

Reid, Kimberly J. ;

Dunlay, Shannon M. ;

Chan, Paul S. ;

Hauptman, Paul J. ;

Zannad, Faiez ;

Konstam, Marvin A. ;

Spertus, John A. .

CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2011, 4 (04) :389-U44

[6] Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction Findings From the I-PRESERVE Trial [J].

Anand, Inder S. ;

Rector, Thomas S. ;

Cleland, John G. ;

Kuskowski, Michael ;

McKelvie, Robert S. ;

Persson, Hans ;

McMurray, John J. ;

Zile, Michael R. ;

Komajda, Michel ;

Massie, Barry M. ;

Carson, Peter E. .

CIRCULATION-HEART FAILURE, 2011, 4 (05) :569-577

[7] Prevalence, Clinical Phenotype, and Outcomes Associated With Normal B-Type Natriuretic Peptide Levels in Heart Failure With Preserved Ejection Fraction [J].

Anjan, Venkatesh Y. ;

Loftus, Timothy M. ;

Burke, Michael A. ;

Akhter, Nausheen ;

Fonarow, Gregg C. ;

Gheorghiade, Mihai ;

Shah, Sanjiv J. .

AMERICAN JOURNAL OF CARDIOLOGY, 2012, 110 (06) :870-876

[8] Obstructive sleep apnea syndrome affects left ventricular diastolic function -: Effects of nasal continuous positive airway pressure in men [J].

Arias, MA ;

García-Río, F ;

Alonso-Fernández, A ;

Mediano, O ;

Martínez, I ;

Villamor, J .

CIRCULATION, 2005, 112 (03) :375-383

[9] Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction >=40% treated with diuretics plus angiotensin-converting enzyme inhibitors [J].

Aronow, WS ;

Ahn, C ;

Kronzon, I .

AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (02) :207-209

[10] EFFECT OF ENALAPRIL ON CONGESTIVE-HEART-FAILURE TREATED WITH DIURETICS IN ELDERLY PATIENTS WITH PRIOR MYOCARDIAL-INFARCTION AND NORMAL LEFT-VENTRICULAR EJECTION FRACTION [J].

ARONOW, WS ;

KRONZON, I .

AMERICAN JOURNAL OF CARDIOLOGY, 1993, 71 (07) :602-604

← 1 2 3 4 5 6 7 8 9 10 →